請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70206
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 湯明哲(Ming-Je Tang) | |
dc.contributor.author | Chiung-Yu Chen | en |
dc.contributor.author | 陳炯瑜 | zh_TW |
dc.date.accessioned | 2021-06-17T03:49:21Z | - |
dc.date.available | 2028-12-31 | |
dc.date.copyright | 2018-03-01 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-01-22 | |
dc.identifier.citation | 司徒達賢,1995,策略管理(初版),台北市:遠流出版事業股份有限公司。
司徒達賢,2003,策略管理案例解析:觀念與實例(初版),台北市:智勝文化事業有限公司。 朱文儀,2000,多角化企業之協調機制:資訊處理觀點、情境理論,與資源基礎觀點之整合,行政院國家科學委員會專題研究計劃成果報告,計劃編號:NSC89-2416-H-002-036。 李吉仁,1999,我國集團企業成長策略選擇與分子企業經營績效之研究,行政院國家科學委員會專題研究計畫成果報告,計畫編號:NSC 88-2416-H-002-040。 杜麗華,2014,食在健康2:知心地球 在地99 宅配周記(初版),臺北市,媚登峯集團。 邱正仁、薛明賢與陳虹君,2010,多角化企業之投資策略與融資策略之探討,財務金融學刊,18卷,2期:99-133。 邱麗珍,2001,女性雜誌中美容美體論述的解構,國立臺灣師範大學家政教育研究所未出版之碩士論文。 洪世章與陳忠賢,2000,臺灣企業集團的發展是漸趨同形嗎?,臺大管理論叢,11卷1期:頁73-101。 倪衍森、黃寶玉與康唯珍,2011,公司治理會增強或削弱競爭力與多角化對公司價值影響?,商管科技季刊,12卷2期:175-208。 寇怡衡,2014,口服減肥藥市場現況及趨勢淺析,財團法人生物技術開發中心。 張淑珍,1987,某大學女生體型意識、肥胖度、健康與飲食生活關係之研究,國立陽明大學公共衛生研究所未出版之碩士論文。 曹壽民、金成隆與呂學典,2011,股權結構與多角化,臺大管理論叢,22卷1 期:165-198。 郭婉萍,2000,某專科女學生減重意圖及其相關因素之研究,國立臺灣師範大學衛生教育研究所未出版之碩士論文。 陳一如,2009,創新能力與公司治理程度對多角化公司價值的影響:以臺灣電子業為例,管理評論, 28卷, 2期:51-75。 陳建宏與李昀庭,2015,台灣傳統產業公司之多角化與財務績效,財金論文叢刊,22期:54-65。 陳秋伶,2014,從全球細胞治療產業看台灣的發展契機 生技醫藥產業評析,財團法人生物技術開發中心。 陳淑芳,2010,全球消費者減重需求及相關產品之開發,食品工業發展研究所。 湯明哲,1999,機會基礎的與能力基礎的多角化策略之實證研究:中、日、韓石化廠商之比較分析,行政院國家科學委員會專題研究計畫成果報告,計畫編號:88-2416-H-002-027。 湯明哲,2003,策略精論:基礎篇(第一版),台北市:天下遠見。 經濟部統計處,1999,中華民國臺灣地區企業多角化調查報告:中華民國八十七年調查,臺北市:經濟部。 趙月秀,2002,再生醫學技術發展藍圖,財團法人生物技術開發中心。 蔡孟娟,1999,女性服用瘦身或美容產品之影響因素分析,國立臺灣大學衛生政策與管理研究所未出版之碩士論文。 衛生福利部,2016,中華民國一〇四年全民健康保險醫療統計,臺北市:衛生福利部。 鄭佩綺,2010,全球再生醫學市場解析,工業技術研究產業經濟與趨勢研究中心。 鄭美瓊,2003,某大學女生外表吸引力知覺與塑身美容行為之研究,國立臺灣師範大學衛生教育研究所未出版之碩士論文。 謝秀欣,2017,再生醫學大躍進-初勘再生醫學研究新進展,工業技術研究產業經濟與趨勢研究中心。 聶西平,1998,瘦身廣告之內容分析,國立台灣大學公共衛生研究所未出版之碩士論文。 羅勻廷,2005,國際專業美容瘦身會館-會員消費動機之個案研究,亞洲大學經營管理研究所未出版之碩士論文。 欒錦榮,2008,多角化進入新興產業策略之研究:進入可能性與進入時機,國立台灣大學國際企業學研究所未出版之博士論文。 Abell, D. F. 1980. Defining the Business: The Starting Point of Strategic Planning. Englewood Cliffs, N.J: Prentice-Hall. Ahuja, G., and Katila, R. 2001. Technological acquisitions and the innovation performance of acquiring firms: A longitudinal study. Strategic Management Journal, 22: 197-220. Ahuja, G., and Novelli, E. 2017. Redirecting research efforts on the diversification-performance linkage: The search for synergy. The Academy of Management Annals, 11(1):342-390. Amit, R., and Livnat, J. 1988. Diversification strategies, business cycles and economic performance. Strategic Management Journal, 9: 99-110. Anderson, R. C., Bizjak, J. M., Lemmon, M. L., and Bates, T. W. 2000. Corporate governance and firm diversification. Financial Management, 29(1): 5-22. Ansoff, H. 1958. A model for diversification. Management Science. 4(4):392-414. Arrow, K. E. 1974. The Limits of Organization. New York, NY: Norton. Basharut, A. S. and James, B. E. 2013. Stem cell therapy market. Nature Reviews Drug Discovery, 12(3): 185-186. Baum, J. A., and Korn, H. J. 1999. Dynamics of dyadic competitive interaction. Strategic Management Journal, 20: 251-278. Berger, and Ofek. 1995. Diversification's effect on firm value. Journal of Financial Economics, 37(1), 39-65. Berry, C. H. 1971. Corporate growth and diversification. The Journal of Law and Economics, 14(2): 371-383. Berry, C. H. 1974. Corporate diversification and market structure. Bell Journal of Economics and Management Science, 5: 196-204. Bettis, R. A. 1981. Performance differences in related and unrelated diversified firms. Strategic Management Journal, 2: 379-393. Bettis, R. A., and Hall, W. K. 1982. Diversification strategy, accounting determined risk, and accounting determined return. Academy of Management Journal, 25:254-264. Chandler, A. D. Jr. 1962. Strategy and Structure: Chapters in the History of the Industrial Enterprise. Cambridge, MA: MIT Press. Chang, S. J. 1996. An evolutionary perspective on diversification and corporate restructuring: Entry, exit, and economic performance during 1981-89. Strategic Management Journal, 17: 587-611. Christensen, H. K., and Montgomery, C. A. 1981. Corporate economic performance: Diversification strategy versus market structure. Strategic Management Journal, 2: 327-343. Chuang, C. M., and Chu, W. Y. 1999. Decision-Making Autonomy and Divisional Effectiveness in Multibusiness Firms: From Contingency Perspective to Cultural Control Perspective. Asia Pacific Management Review, 4(4): 345-356. Chung, H. J. 2005. Domination over Small, Unrelated Ventures and the Effects on the Unrelated Diversification of the Parent Company. Journal of Management. 22(6): 695-708. Davis, R., and Thomas, L. G. 1993. Direct estimation of synergy: A new approach to the diversity-performance debate. Management Science, 39: 1334-1346. Denis, D. J., Denis, D. K., and Sarin, A. 1997. Agency Problems, Equity Ownership, and Corporate Diversification. The Journal of Finance, 52(1), 135-160. Dubofsky, P., and Varadarajan, P. R. 1987. Diversification and measures of performance: Additional empirical evidence. Academy of Management Journal, 30: 597-608. Ehnert, S., Glanemann, M., Schmitt, A., Vogt, S., Shanny, N., Nussler, N., Stöckle, U., Nussler, A. 2009. The possible use of stem cells in regenerative medicine: dream or reality? Langenbeck's Archives of Surgery, 394(6): 985-997. Friedenstein, A. J. 1976. Precursor Cells of Mechanocytes. International Review of Cytology, 47: 327-359. Galbraith, J. R. 1982. Designing the innovating organization. Organizational Dynamics, 10: 5-2. Gort, M. 1962. Diversification and Integration in American Industry. Princeton, NJ: Princeton University Press. Grant, R. M., 2008, Contemporary Strategy Analysis, Malden, MA : Blackwell. Greve, H.R., and Baum, J.A. 2001. Introduction: A multiunit, multimarket world. Advances in Strategic Management, 18: 1-28. Hamel, G., and Prahalad, C. K. 1990. Corporate imagination and expeditionary marketing. Harvard Business Review, 69: 81-92. Harris, M. 1982. Asymmetric information, incentives and intrafirm resource allocation. Management Science : Journal of the Institute for Operations Research and the Management Sciences, 28(6), 604-620. Hart, O., and Tirole, J. 1990. Vertical integration and market foreclosure. Brookings Papers on Economic Activity. Microeconomics, 205-286. Haveman, H. A. 1993. Organizational size and change: Diversification in the savings and loan industry after deregulation. Administrative Science Quarterly, 38: 20-50. Jacquemin, A. P., and Berry, C. H. 1979. Entropy measure of diversification and corporate growth. Journal of Industrial Economics, 27: 359-369. Javidan, M. 1998. Core competence: What does it mean in practice? Long Range Planning, 31(1), 60-71. Jensen, M. C., and Meckling, W. H. 1976. Theory of the firm: Managerial behavior, agency costs and ownership structure. Journal of Financial Economics, 3(4): 305-360. Jones, G.R., and Hill, C.W. 1988. Transaction cost analysis of strategy‐structure choice. Strategic Management Journal, 9: 159-172. Kamien, M. I., and Schwartz, N. L. 1975. Market Structure and Innovation: a Survey. Journal of Economic Literature, 13: 1-37. Kazanjian, R.K., and Drazin, R. 1987. Implementing internal diversification: Contingency factors for organization design choices. Academy of Management Review, 12: 342-354. Keats, B.W., and Hitt, M.A.1988. A causal model of linkages among environmental dimensions, macro organizational characteristics, and performance. Academy of Management Journal, 31: 570-598. Klein, B., Crawford, R. G., and Alchian, A. A. 1978. Vertical integration, appropriable rents, and the competitive contracting process. Journal of Law & Economics, 21: 297-326. Kotler, P. 1988. Marketing Management : Analysis, Planning, Implementation, and Control. Englewood Cliffs, NJ : Prentice Hall. Kuppuswamy, V., and Villalonga, B. 2016. Does diversification create value in the presence of external financing constraints? Evidence from the 2007-2009 financial crisis. Management Science, 62: 905-923. Lang, L., and Stulz, R. M. 1994. Tobin's q, corporate diversification, and firm performance. Journal of Political Economy, 102(6), 1248-1280. Leonard-Barton, D. 1992. Core Capabilities and Core Rigidities: A Paradox in Managing New Product Development. Strategic Management Journal, 13, 111. Li, S. X., and Greenwood, R. 2004. The effect of within industry diversification on firm performance: synergy creation, multi‐market contact and market structuration. Strategic Management Journal, 25:1131-1153. Lubatkin, M., and Chatterjee, S. 1991. The strategy shareholder value relationship: Testing temporal stability across market cycles. Strategic Management Journal, 12: 251-270. Maksimovic, V., and Phillips, G. 2002. Do conglomerate firms allocate resources inefficiently across industries? Theory and evidence. Journal of Finance, 57: 721-767. Martin, J. D., and Sayrak, A. 2003. Corporate diversification and shareholder value: A survey of recent literature. Journal of Corporate Finance, 9 (1): 37-57. Matusik, S. F., and Fitza, M. A. 2012. Diversification in the venture capital industry: Leveraging knowledge under uncertainty. Strategic Management Journal, 33: 407-426. Miller, C. C., Washburn, N. T., and Glick, W. H. 2013. Perspective-The myth of firm performance. Organization Science, 24: 948-964. Miller, D. J., Fern, M. J., and Cardinal, L. B. 2007. The use of knowledge for technological innovation within diversified firms. Academy of Management Journal, 50: 307-325. Mitchell, W., and Singh, K. 1993. Death of the lethargic: Effects of expansion into new technical subfields on performance in a firm’s base business. Organization Science, 4: 152-180. Montgomery, C. A. 1985. Product-market diversification and market power. Academy of Management Journal (pre-1986), 28(4), 789-798. Montgomery, C.A., 1994. Corporate diversification. Journal of Economic Perspectives, 8 (3), 163–178. Normann, R. 1971. Organizational innovativeness: Product variation and reorientation. Administrative Science Quarterly, 16: 203-215. Palich, L. E., Cardinal, L. B., and Miller, C. C. 2000. Curvilinearity in the diversification-performance linkage: An examination of over three decades of research. Strategic Management Journal, 21: 155-174. Penrose, E. T. 1959. The Theory of the Growth of the Firm. Oxford, UK: Basil Blackwell. Pitts, R., and Hopkins, H. 1982. Firm diversity: conceptualization and measurement. The Academy of Management Review, 7(4): 620-629. Prahalad C. K., and Hamel, G. 1990. The core competence of the corporation, strategy, seeking and security competitive advantage. Harvard Business Review Book, 68(3), 79-91. Rajan, R., Servaes, H., and Zingales, L. 2000. The cost of diversity: The diversification discount and inefficient investment. Journal of Finance, 55: 35-80. Ramanujam, V., and Varadarajan, P. 1989. Research on corporate diversification: A synthesis. Strategic Management Journal, 10(6): 523-551. Roberts, E. B., and Berry, C. A. 1985. Entering new businesses: selecting strategies for success, Sloan Management Review, 26(3): 3-17. Rumelt, R. P. 1974. Strategy Structure and Economic Performance. Boston, MA: Division of Research, Harvard Business School. Santalo, J., and Becerra, M. 2008. Competition from specialized firms and the diversification-performance linkage. Journal of Finance, 63: 851-883. Scharfstein, D. S. 1998. The Dark Side of Internal Capital Markets II: Evidence From Diversified Conglomerates (No. w6352), Cambridge, MA: National Bureau of Economic Research. Scharfstein, D. S., and Stein, J. C. 2000. The dark side of internal capital markets: Divisional rent-seeking and inefficient investment. Journal of Finance, 55 (6): 2537-2564. Shin, H. H., and Stulz, R. M. 1998. Are internal capital markets efficient ? Quarterly Journal of Economics, 113: 531-552. Silhan, P. A., and Thomas, H. 1986. Using simulated mergers to evaluate corporate diversification strategies. Strategic Management Journal, 7(6): 523-534. Simmonds, P. G. 1990. The combined diversification breadth and mode dimensions and the performance of large diversified firms. Strategic Management Journal, 11: 399-410. Taubes, G. 2012. Cancer research. Unraveling the obesity-cancer connection. Science, 335(6064): 28-32. Thomas, E. D., Flournoy, N., Buckner, C. D., Clift, R. A., Fefer, A., Neiman, P. E., Storb, R. 1977. Cure of leukemia by marrow transplantation. Leukemia Research, 1(1):67-70. Weston, J. F., and Mansinghka, S. K. 1971. Tests of the efficiency performance of conglomerate firms. Journal of Finance, 26: 919-936. National Center for Complementary and Integrative Health. 2017. Complementary, Alternative, or Integrative Health: What’s In a Name? https://nccih.nih.gov/health/integrative-health. Accesses Dec. 05, 2017. Nobelprize.org. Nobel Media AB. 2014. The Nobel Prize in Physiology or Medicine 1990. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1990/. Accesses Dec. 05, 2017. SRI International. 2005. SRI Alumni Association Newsletter: December 2005. https://www.sri.com/sites/default/files/brochures/dec-05.pdf. Accesses Dec. 05, 2017. The Boston Consulting Group. 1968. The Experience Curve. https://www.bcg.com/publications/1968/business-unit-strategy-growth-experience-curve.aspx . Accesses Dec. 05, 2017. The Boston Consulting Group. 1970. The Product Portfolio. https://www.bcg.com/publications/1970/strategy-the-product-portfolio.aspx. Accesses Dec. 05, 2017. The Boston Consulting Group. 2013. BCG Classics Revisited: The Experience Curve. https://www.bcg.com/publications/2013/growth-business-unit-strategy-experience-curve-bcg-classics-revisited.aspx . Accesses Dec. 05, 2017. The Boston Consulting Group. 2014. BCG Classics Revisited: The Growth Share Matrix. https://www.bcg.com/zh-cn/publications/2014/growth-share-matrix-bcg-classics-revisited.aspx. Accesses Dec. 05, 2017. U.S. National Library of Medicine. ClinicalTrials.gov. https://www.clinicaltrials.gov/. Accesses Dec. 05, 2017. World Health Organization. Obesity and overweight. 2017. http://www.who.int/mediacentre/factsheets/fs311/en/. Accesses Dec. 05, 2017. 中時電子報,2017,幹細胞可促褐色脂肪合成 打擊肥胖,http://www.chinatimes.com/realtimenews/20170911005366-260418,搜尋日期:2017年12月05日。 內政部統計處,2017,106年第10週內政統計通報(我國老年人口數首次超過幼年人口數),http://www.moi.gov.tw/stat/news_content.aspx?sn=11735,搜尋日期:2017年12月05日。 公平交易委員會,2016,公平交易委員會對於瘦身美容案件之處理原則,http://www.ftc.gov.tw/internet/main/doc/docDetail.aspx?uid=165&docid=12224,搜尋日期:2017年12月05日。 台灣癌症登記中心,2009,年齡標準化發生率長期趨勢(資料僅含侵襲癌)十大癌症,http://tcr.cph.ntu.edu.tw/main.php?Page=A5B2,搜尋日期:2017年12月05日。 長春藤生物科技,2017,長春藤與慈濟醫院幹細胞合作記者會!http://www.icarecell.com/archives/2218,搜尋日期:2017年12月05日。 風傳媒,2017,長春藤幹細胞保存庫和花蓮慈濟醫學中心 攜手研究 脂肪幹細胞促進褐色脂肪合成,提升體內代謝能力並有效抑制肥胖,http://www.storm.mg/stylish/329410,搜尋日期:2017年12月05日。 經濟部中小企業處,2017,2017年中小企業白皮書,http://book.moeasmea.gov.tw/book/doc_detail.jsp?pub_SerialNo=2017A01295&click=2017A01295#,搜尋日期:2017年12月05日。 經濟部技術處,2014,A+企業創新研發淬鍊計畫,http://aiip.tdp.org.tw/index.php,搜尋日期:2017年12月05日。 衛生福利部,1999,瘦身美容業管理規範,http://mohwlaw.mohw.gov.tw/FLAW/FLAWDAT0202.aspx?lsid=FL013875,搜尋日期:2017年12月05日。 衛生福利部,1999,瘦身美容業廣告規範,http://mohwlaw.mohw.gov.tw/FLAW/FLAWDAT0202.aspx?lsid=FL013876,搜尋日期:2017年12月05日。 衛生福利部,2002,人體細胞組織優良操作規範,http://mohwlaw.mohw.gov.tw/FLAW/FLAWDAT0201.aspx?lsid=FL022759,搜尋日期:2017年12月05日。 衛生福利部,2015,人體器官移植條例,http://mohwlaw.mohw.gov.tw/FLAW/FLAWDAT0202.aspx?lsid=FL013537,搜尋日期:2017年12月05日。 衛生福利部,2017,「細胞及基因治療產品管理法(草案)」徵求各界意見,https://www.mohw.gov.tw/cp-16-36954-1.html,搜尋日期:2017年12月05日。 衛生福利部,2017,人體器官保存庫許可通過名單,https://consumer.fda.gov.tw/Human/CellLibrary.aspx?nodeID=377,搜尋日期:2017年12月05日。 衛生福利部食品藥物管理署,2013,瘦身美容定型化契約,https://www.fda.gov.tw/tc/lawContent.aspx?id=1581&chk=5e1c0321-ca33-4215-a2b2-e873fa267d33¶m=pn=2&cid=55&cchk=f2d99f85-142b-4517-86c1-571ecbb15758,搜尋日期:2017年12月05日。 衛生福利部食品藥物管理署,2015,公告「人類細胞治療產品查驗登記審查基準」,http://www.fda.gov.tw:8080/pda/page01Content.aspx?id=13854&chk=644c899e-91b7-43e8-8d32-3d09d1420d5e¶m=&pn=43,搜尋日期:2017年12月05日。 衛生福利部食品藥物管理署,2015,公告「人類細胞治療產品捐贈者合適性判定基準」,http://www.fda.gov.tw:8080/pda/page01Content.aspx?id=14125&chk=ab135b79-2022-47ed-a13e-469ab5479916¶m=&pn=39,搜尋日期:2017年12月05日。 衛生福利部食品藥物管理署,2015,回顧103年藥品審查革新成果,迎接104年藥品管理新時代,https://www.mohw.gov.tw/cp-207-21194-1.html,搜尋日期:2017年12月05日。 衛生福利部食品藥物管理署,2016,「人體試驗管理辦法」修法,有限度開放附屬計畫,http://www.mohw.gov.tw/fp-2626-14378-1.html,搜尋日期:2017年12月05日。 衛生福利部統計處,2008,83年度死因統計,https://dep.mohw.gov.tw/DOS/lp-1841-113.html,搜尋日期:2017年12月05日。 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70206 | - |
dc.description.abstract | 成長,是企業追求的重要目標,途徑包括了本業內部成長以及透過多角化尋找成長機會。
本論文研究個案為台灣瘦身美容公司,發展成為連鎖企業後,初期著眼於產品與服務的發展以及創新來滿足客戶需求。隨著環境變化,個案以內部發展、策略聯盟、授權、合資以及併購等方式把經營觸角伸向其他領域,並轉型成為健康管理公司以及再生醫學生物科技公司。 研究針對多角化的多個面向,包括動機、方向、綜效與成本,回顧過去,探討個案發展近四十年來,隨著外在環境及內部因素的影響,於各個階段如何建構核心競爭力以及延伸核心競爭力所面對的困難。 文末就研究結果提出建議,並展望未來,作為相關產業進行多角化轉型的參考。 | zh_TW |
dc.description.abstract | Growth, one of the significant goals pursued by enterprises, may be achieved through either the expansion of existing businesses or the opportunities from diversified external resources.
This study focuses on the case of a chain enterprise in Taiwan (the “Company”) which devoted to the slimming and beauty industry. The Company met the customers’ needs by improving and innovating its own products and services during the initial stage. Following the change of business environment, the Company extended its business to various fields through internal development, strategic alliances, licensing, joint ventures, merger and acquisitions, transforming itself into a healthcare management company as well as a regenerative medical biotechnology company. From particular aspects of diversification, including the motivation, direction, efficiency, and cost, this study aims at how the Company enhanced its core competitiveness and extended core competitiveness to face the challenges from external environments and internal factors in respective of the period of nearly 40 years. Through the analysis of the Company, this study concludes with farsighted suggestions, looking forward to providing some references to the diversified transformation for the related industries. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:49:21Z (GMT). No. of bitstreams: 1 ntu-107-P04746008-1.pdf: 2170101 bytes, checksum: ebd2e0264a001573b8ba42b03cc8a89f (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 誌 謝 II
中文摘要 III THESIS ABSTRACT IV 目錄 V 圖目錄 VIII 表目錄 X 第一章 緒 論 1 第一節、研究背景 1 第二節、研究問題與目的 2 第三節、研究範圍 3 一、研究方法與資料來源 3 二、研究限制 3 第四節、論文架構 4 第二章 文獻探討 5 第一節、企業成長與多角化策略 6 第二節、多角化的定義 7 第三節、多角化的動機 8 一、股東價值最大化、綜效追求之多角化 10 二、股東價值最大化、非綜效追求之多角化 12 三、非股東價值最大化之多角化 13 四、多角化綜效 13 五、多角化成本 14 第四節、多角化的方向、模式及態樣 16 第五節、多角化與績效 19 一、衡量績效的方式 19 二、影響績效的因素 20 第六節、多角化分析 24 一、SWOT分析 24 二、成長占有矩陣分析 25 第三章 個案企業簡介 29 第一節、瘦身美容時期 30 第二節、預防醫學時期 34 第三節、再生醫學時期 37 第四章 討論與分析 42 第一節、瘦身美容時期 43 一、多角化的動機 43 二、多角化的方向 44 三、多角化的進入方式 44 四、多角化的狀態 45 五、多角化企業的管理 46 六、多角化的績效與成本 47 第二節、預防醫學時期 51 一、多角化的動機 51 二、多角化的方向 52 三、多角化的進入方式 52 四、多角化的狀態 53 五、多角化企業的管理 53 六、多角化的績效與成本 54 第三節、再生醫學時期 56 一、多角化的動機 56 二、多角化的方向 56 三、多角化的進入方式 57 四、多角化的狀態 58 五、多角化企業的管理 58 六、多角化的績效與成本 59 第四節、小結 61 第五章 結論與建議 65 第一節、研究結論 66 第二節、建議 69 參考文獻 73 中文 73 英文 75 網路資料 79 附錄 81 瘦身美容業管理規範 81 瘦身美容業廣告規範 82 公平交易委員會對於瘦身美容案件之處理原則 83 人體細胞組織優良操作規範 85 細胞及基因治療產品管理法(草案) 94 | |
dc.language.iso | zh-TW | |
dc.title | 策略轉型與事業多角化:媚登峯集團個案研究 | zh_TW |
dc.title | Strategic Transformation and Business Diversification: The Matinform Group Case Study | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 吳政衛(Cheng-Wei Wu),陳瑀屏(Yu-Ping Chen) | |
dc.subject.keyword | 瘦身美容業,健康管理,再生醫學,策略轉型,事業多角化, | zh_TW |
dc.subject.keyword | Slimming and Beauty Industry,Healthcare Management,Regenerative Medicine,Strategic Transformation,Business Diversification, | en |
dc.relation.page | 95 | |
dc.identifier.doi | 10.6342/NTU201800120 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-01-22 | |
dc.contributor.author-college | 管理學院 | zh_TW |
dc.contributor.author-dept | 國際企業管理組 | zh_TW |
顯示於系所單位: | 國際企業管理組 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 2.12 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。